189 related articles for article (PubMed ID: 24568609)
1. In vitro evaluation and in vivo performance of lyophilized gliclazide.
Mansour HF; Aly UF
Drug Dev Ind Pharm; 2015 Apr; 41(4):650-7. PubMed ID: 24568609
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro evaluation of a solid dispersion system of gliclazide:PEG 6000.
Asyarie S; Rachmawati H
PDA J Pharm Sci Technol; 2007; 61(5):400-10. PubMed ID: 18047178
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical investigations and stability studies of amorphous gliclazide.
Jondhale S; Bhise S; Pore Y
AAPS PharmSciTech; 2012 Jun; 13(2):448-59. PubMed ID: 22382730
[TBL] [Abstract][Full Text] [Related]
4. Dissolution rate enhancement of gliclazide by ordered mixing.
Saharan VA; Choudhury PK
Acta Pharm; 2011 Sep; 61(3):323-34. PubMed ID: 21945911
[TBL] [Abstract][Full Text] [Related]
5. IDENTIFICATION OF PHARMACEUTICAL EXCIPIENT BEHAVIOR OF CHICKPEA (CICER ARIETINUM) STARCH IN GLICLAZIDE IMMEDIATE RELEASE TABLETS.
Meka VS; Yee P; Sheshala R
Acta Pol Pharm; 2016; 73(2):469-78. PubMed ID: 27180440
[TBL] [Abstract][Full Text] [Related]
6. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes.
Aggarwal S; Singh PN; Mishra B
Pharmazie; 2002 Mar; 57(3):191-3. PubMed ID: 11933849
[TBL] [Abstract][Full Text] [Related]
7. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.
Moes J; Koolen S; Huitema A; Schellens J; Beijnen J; Nuijen B
Eur J Pharm Biopharm; 2013 Jan; 83(1):87-94. PubMed ID: 23085332
[TBL] [Abstract][Full Text] [Related]
8. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
9. Preparation and physicochemical characterization of binary and ternary ground mixtures of carvedilol with PVP and SLS aimed to improve the drug dissolution.
Bolourchian N; Talamkhani Z; Nokhodchi A
Pharm Dev Technol; 2019 Nov; 24(9):1115-1124. PubMed ID: 31282827
[TBL] [Abstract][Full Text] [Related]
10. To evaluate the change in release from solid dispersion using sodium lauryl sulfate and model drug sulfathiazole.
Dave RH; Patel HH; Donahue E; Patel AD
Drug Dev Ind Pharm; 2013 Oct; 39(10):1562-72. PubMed ID: 23030270
[TBL] [Abstract][Full Text] [Related]
11. Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide.
El-Maghraby GM; Alomrani AH
Pak J Pharm Sci; 2011 Oct; 24(4):459-68. PubMed ID: 21959805
[TBL] [Abstract][Full Text] [Related]
12. Amorphous solid dispersion of berberine with absorption enhancer demonstrates a remarkable hypoglycemic effect via improving its bioavailability.
Zhaojie M; Ming Z; Shengnan W; Xiaojia B; Hatch GM; Jingkai G; Li C
Int J Pharm; 2014 Jun; 467(1-2):50-9. PubMed ID: 24607213
[TBL] [Abstract][Full Text] [Related]
13. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
14. New metastable form of glibenclamide prepared by redispersion from ternary solid dispersions containing polyvinylpyrrolidone-K30 and sodium lauryl sulfate.
Thongnopkoon T; Puttipipatkhachorn S
Drug Dev Ind Pharm; 2016 Jan; 42(1):70-79. PubMed ID: 25835067
[TBL] [Abstract][Full Text] [Related]
15. Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations.
Miro A; Quaglia F; Sorrentino U; La Rotonda MI; D'Emmanuele Di Villa Bianca R; Sorrentino R
Eur J Pharm Sci; 2004 Sep; 23(1):57-64. PubMed ID: 15324923
[TBL] [Abstract][Full Text] [Related]
16. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
17. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system.
Yang Y; Zhao Z; Wang Y; Yang L; Liu D; Yang X; Pan W
Int J Pharm; 2016 Jun; 506(1-2):340-50. PubMed ID: 27132166
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion.
Khattab IS; Nada A; Zaghloul AA
Drug Dev Ind Pharm; 2010 Aug; 36(8):893-902. PubMed ID: 20196643
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.
Yin LF; Huang SJ; Zhu CL; Zhang SH; Zhang Q; Chen XJ; Liu QW
Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267
[TBL] [Abstract][Full Text] [Related]
20. Physicochemical characterization of artemether solid dispersions with hydrophilic carriers by freeze dried and melt methods.
Ansari MT; Karim S; Ranjha NM; Shah NH; Muhammad S
Arch Pharm Res; 2010 Jun; 33(6):901-10. PubMed ID: 20607495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
